LifeSpan Bio acquires Everest Biotech to expand reagent portfolio
Category: #health  By Mateen Dalal  Date: 2019-07-17
  • share
  • Twitter
  • Facebook
  • LinkedIn

LifeSpan Bio acquires Everest Biotech to expand reagent portfolio

The transaction will be LifeSpan BioSciences’ second investment this year following its Nordic-MUbio acquisition

LifeSpan BioSciences (LSBio), a provider of life science research reagents and antibodies, has recently announced that it has acquired Everest Biotech, a certified expert in antigen polyclonal antibodies. The acquisition  will help LifeSpan BioSciences expand its product offering and strengthen its position as the fastest growing provider in the market for research reagent.

LSBio, though this partnership, will offer a comprehensive reagents catalogue which can be combined with the wide range of IHC validated primary antibodies.

Heather Holemon, LSBio’s CEO said that the company is looking forward to adding the product range produced by Everest Biotech to its portfolio. The offerings by Everest Biotech stand out owing to their exceptional high quality, which will perfectly complement LSBio’s existing portfolio.

Citing reliable sources, Everest Biotech is committed towards continuous improvement and quality that has ensured the growth of the company’s catalogue. It now has scores of goat antibodies against a wide range of mouse, rat and human targets in the biomedical space.

LSBio’s offering of more than 500,000 polyclonal and monoclonal primary antibodies will expand to include all protein in the proteome after the acquisition. Over 15,000 antibodies of LSBio have been identified as IHC reagents that are exceptional and have been given the IHC-plus brand through the extensive in-house testing.

Apparently, after LSBio acquired Nordic-MUbio in February, the Everest Bio acquisition will mark the second investment made by the company this year.

For the uninitiated, LifeSpan BioSciences, Inc. provides IHC validated reagent antibodies along with services to the global community of pharmaceutical, biotech and academic researchers and has been a leader in the industry after its inception in 1995.

The company has built a catalogue that contains over 750,000 antibodies, proteins, biochemicals and assay kits which it sells through the network of its international distributors.

 

Source Credit-https://finance.yahoo.com/news/lifespan-biosciences-announces-acquisition-everest-080000460.html

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

PayPal buys Happy Returns to strengthen reverse logistics system
PayPal buys Happy Returns to strengthen reverse logistics system
By Mateen Dalal

U.S. based digital payments platform, PayPal, an online payment system entity has announced the purchase of Happy Returns- a returns solution firm that provides online buyers access to simplified ways to return unwanted merchandise to retailers; elim...

YOP officially unveils YOP app to ease access to DeFi for the masses
YOP officially unveils YOP app to ease access to DeFi for the masses
By Mateen Dalal

Yield Optimization Platform and Protocol (YOP) recently declared its official launch of YOP application; the first all-in-one mobile app which makes it quite easier for everyone to access DeFi. The V0 version of the app is now available for early acc...

Singapore to create second national supercomputer with more on roadmap
Singapore to create second national supercomputer with more on roadmap
By Mateen Dalal

Following its success of the first supercomputer system, Singapore is set to build its upcoming second supercomputer system in an attempt to strengthen the local research community, offering 8X more computing capacity than its previous model. The sy...